ISR Articles
-
Revealing Response To A Hypothetical Question About Outsourcing Services
If you were in charge of establishing a bioprocessing contract manufacturing business, which service provider attributes would you implement to ensure your company’s success? Here's how peers in the industry responded.
-
Is OSD Becoming More Complicated?
Are CDMOs evaluated on the same metrics for simple and complex oral dose manufacturing projects? Gain insight into data from ISR’s new report to provide answers to these questions and more.
-
Small & Emerging Outsourced Manufacturing Activities
To better understand the outsourcing practices used by respondents’ companies, ISR asked research participants to provide an estimate for various manufacturing activities.
-
Small And Emerging Biopharma Companies Outsourcing Practices
There is no question that the drug development services industry is complex, dynamic, and continuously evolving. While every sponsor company is different, all can benefit from keeping a pulse on current outsourcing practices and the activities being outsourced. Over the past year, ISR conducted several research activities with the aim of better understanding the needs of small and emerging biopharma companies and how they differ from the larger industry players. This article highlights the results of this survey.
-
Old Dog, New Tricks: How Pharma Is Innovating With Existing Technologies
Innovation in clinical technologies sometimes comes in the shape of disruptive new technologies or as a series of incremental changes and improvements. Find out how new data is revealing positive changes and existing tech solutions are now being used in new ways.
-
How To Improve Outsourcing Relationships
ISR's Development and Commercial Outsourcing Models report indicates that proactive communication between sponsors and CMOs in these three areas will help to improve outsourcing relationships.
-
Improving Manufacturing Outsourcing Relationships
In Q4, 2018, ISR asked 100 sponsors who outsource manufacturing about several different scenarios that could potentially improve outsourcing relationships. The data below show how each of the scenarios panned out. A key common element across the most likely scenarios—communication.
-
Are Preferred Provider Agreements The Best Model For Outsourcing?
ISR has observed use of preferred provider agreements (PPAs) and the proportion of outsourcing allocated to preferred providers increase over the past three years.
-
Why Is It So Hard To Select A CMO?
What can be done to alleviate some of the challenges in CMO selection? Learn the unexpected findings from the Industry Standard Research Outsourcing Models survey, from the perspective of a market researcher.
-
Customer Loyalty In Small Molecule Drug Product Manufacturing
In Q42020, ISR surveyed 123 sponsors who outsource small molecule drug product to gain insight into customer loyalty. CMO loyalty is computed as an index that consists of overall satisfaction, willingness to recommend, and the likelihood of using the contract manufacturer again.